Geron Corporation
- GERN
- NASDAQ
- Biotechnology
- Telomerase Inhibitor (Imetelstat)
- Myeloid Blood Cancer Therapies
$1.17
Today −4.88%Quote Oct 16, 2026, 08:00 PM UTC
−11.36%over the last month
Max drawdown −11.4%From 1-month high −11.4%3 months −18.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$751.7M
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$5.89
+403.4% from here
Floor
$1.14
2.9% below price
Where the price sits
22 analysts
Analyst range, low to high
$4.00$8.00
- Price $1.17
- Resistance $1.18
- Consensus $5.89
The price is right under resistance. Analysts' average target sits about 403% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GERNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $129.9M
- Revenues Before Adjustments$72.4M55.8%
- Product$57.5M44.2%
Industry
Biotechnology
Employees
258